The aim of our study was to evaluate whether a single dose of cerivastatin at the time of admission of patients with unstable angina pectoris (UAP) or non-Q-wave myocardial infarction (NQMI) can influence the serum level of C-reactive protein (CRP), interleukin-6 (IL-6) and interleukin-8 (IL-8) 24 h later. Forty-four patients with rest chest pain and subendocardial ischemia on ECG were randomized to receive cerivastatin 0.3 mg at the time of admission (group C+) to standard therapy or to remain just on standard therapy (group C-). Blood samples for determination of troponin I (TI), CRP, IL-6 and IL-8 were collected at admission (entry level) and 24 h later (final level). Patients with non-physiological baseline levels of TI, as well as patients with progression to Q wave MI were excluded. All baseline, clinical and demographic data and final values of TI were comparable in the two groups. In patients treated with cerivastatin (group C+, n = 13) we observed decrease in the CRP level (-6.73 +/- 3.93 mg/L); on the other hand, in group C- (n = 17) the CRP level increased (+7.92 +/- 2.77 mg/L, p = 0.004). Similar differences were observed also in IL-6: in group C+ the level was significantly reduced as compared with the increase in group C- (-0.76 +/- 0.52 vs. 4.58 +/- 1.49 ng/L, p = 0.005). The level of IL-8 was not affected. Our results suggest that early treatment with cerivastatin can decrease the serum level of CRP and IL-6 in patients with UAP/NQMI; this might positively influence their prognosis. Nevertheless, further studies are needed to support this hypothesis.

Department of Internal Medicine University Hospital Motol 2nd Medical Faculty Charles University Prague Czech Republic

Zobrazit více v PubMed

N Engl J Med. 1995 Nov 16;333(20):1301-7 PubMed

Nature. 1990 Feb 1;343(6257):425-30 PubMed

Lancet. 1997 Feb 15;349(9050):462-6 PubMed

Clin Chem. 2001 Mar;47(3):403-11 PubMed

N Engl J Med. 2001 Jun 28;344(26):1959-65 PubMed

J Am Coll Cardiol. 2000 Nov 15;36(6):1774-80 PubMed

N Engl J Med. 1996 Oct 3;335(14):1001-9 PubMed

Am J Cardiol. 1990 Feb 1;65(5):297-302 PubMed

JAMA. 2001 Jul 4;286(1):64-70 PubMed

Ann Med. 2001 Feb;33(1):37-47 PubMed

Br J Pharmacol. 2001 Oct;134(4):753-62 PubMed

Circulation. 1996 Sep 1;94(5):874-7 PubMed

Clin Chem Lab Med. 1999 May;37(5):495-503 PubMed

Circ Res. 2001 Oct 26;89(9):763-71 PubMed

Lancet. 1999 Jan 9;353(9147):118-9 PubMed

J Pharmacol Exp Ther. 2000 Sep;294(3):1043-6 PubMed

Circulation. 1992 Sep;86(3):790-7 PubMed

Circulation. 2001 Mar 6;103(9):1191-3 PubMed

Coron Artery Dis. 2001 Mar;12(2):143-8 PubMed

Circulation. 1998 Sep 1;98(9):839-44 PubMed

Lab Invest. 2000 Jul;80(7):1095-100 PubMed

Hypertension. 2000 Sep;36(3):325-9 PubMed

Circulation. 2001 Feb 20;103(7):993-9 PubMed

Int J Immunopharmacol. 1996 Nov;18(11):669-75 PubMed

J Leukoc Biol. 1994 Jun;55(6):749-55 PubMed

Lancet. 1999 Mar 20;353(9157):983-4 PubMed

J Am Coll Cardiol. 1998 Dec;32(7):2057-64 PubMed

Am J Cardiol. 2001 Aug 15;88(4):431-3 PubMed

Life Sci. 2000 Jul 14;67(8):863-76 PubMed

Circulation. 2001 Apr 17;103(15):1933-5 PubMed

Circulation. 2000 Apr 18;101(15):1760-3 PubMed

Lancet. 1994 Nov 19;344(8934):1383-9 PubMed

N Engl J Med. 1994 Aug 18;331(7):417-24 PubMed

J Am Coll Cardiol. 2000 Aug;36(2):427-31 PubMed

J Am Coll Cardiol. 2000 Sep;36(3):970-1062 PubMed

J Am Coll Cardiol. 1998 Jun;31(7):1460-5 PubMed

JAMA. 2001 Apr 4;285(13):1711-8 PubMed

Statins as first-line therapy for acute coronary syndrome?

Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)

Immediate effect of fluvastatin on lipid levels in acute coronary syndrome

Statins in the first-line therapy of acute coronary syndrome - similar to aspirin?

Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696]